相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study
Eiichi Ogawa et al.
HEPATOLOGY RESEARCH (2019)
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
Mitsutaka Osawa et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
Roberta D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2019)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
Hidenori Toyoda et al.
HEPATOLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
Kazuaki Chayama et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study
Juergen K. Rockstroh et al.
CLINICAL INFECTIOUS DISEASES (2018)
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles et al.
HEPATOLOGY (2018)
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure
Fred Poordad et al.
HEPATOLOGY (2018)
EASL Recommendations on Treatment of Hepatitis C 2018
JOURNAL OF HEPATOLOGY (2018)
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti et al.
JOURNAL OF HEPATOLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
Preethi Krishnan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
Paul Y. Kwo et al.
JOURNAL OF HEPATOLOGY (2017)
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns et al.
LANCET INFECTIOUS DISEASES (2017)
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment
Edward Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors
Yoshihito Uchida et al.
PLOS ONE (2014)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
CT Wai et al.
HEPATOLOGY (2003)
分享论文
